Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04426461 · ClinicalTrials.gov registry record · NA

Approach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)

A NA study of Depression and Anxiety, sponsored by Laureate Institute for Brain Research.

Recruiting
Registry status
NA
Development phase
220
Enrollment target
1
Study location

NCT04426461 is a NA study of Depression and Anxiety that is actively recruiting participants, run by Laureate Institute for Brain Research. The registered enrollment target is 220 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04426461, a NA study of Depression and Anxiety, is actively recruiting participants, sponsored by Laureate Institute for Brain Research.

RECRUITING
Registry status
NA
Development phase
220 participants
Enrollment target
1
Study location

Study Summary

Depression and anxiety disorders rank in the top ten causes of years lived with disability. Less than 50% of patients experiencing long-lasting improvements to current gold-standard treatments. Two gold-standard behavioral interventions include behavioral activation, focused on enhancing approach behavior towards meaningful activities, and exposure-based therapy, focused on decreasing avoidance and challenging negative expectations. While these interventions have divergent treatment targets, there is little knowledge to inform which strategies should be used in the frequent case of comorbid anxiety and depression. Approach-avoidance decision-making paradigms focus on assessing responses when faced with potential rewards and threats, tapping into processes important for both anxiety and depression as well as behavioral activation and exposure-based therapy. For this study, investigators will recruit individuals reporting both anxiety and depression symptoms and randomize them to one of three different interventions: (1) behavioral activation, (2) exposure-based therapy, and a non-specific therapy approach (3) supportive therapy. Participants will complete clinical, self-report, behavioral, and functional magnetic resonance imaging (fMRI) assessments before and after therapy. Investigators will use a computational approach to model factors that may influence one's behavior during approach-avoidance decision-making, including drives to avoid threat versus approach reward and confidence versus uncertainty in one's decisions. This project will accomplish the following aims (1) Determine how changes in brain and behavior responses during approach-avoidance conflict relate to changes in mental health symptoms with the different therapy approaches, (2) Determine the degree to which baseline brain and behavior responses during approach-avoidance conflict predict response to the different therapy approaches, above and beyond the influence of demographics and baseline sympto

Conditions Studied

Interventions

  • BEHAVIORAL Behavioral Activation
  • BEHAVIORAL Exposure-based therapy
  • BEHAVIORAL Supportive therapy

Study Locations (1)

Oklahoma

  • Laureate Institute for Brain Research - Tulsa

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2020-09-11
Est. Completion 2025-06-30
Phase NA

What the Registry Record Tells You About NCT04426461

The ClinicalTrials.gov registry entry for NCT04426461 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (72% lower). The listed sponsor is Laureate Institute for Brain Research, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Behavioral Activation is the first listed.

NCT04426461 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT04426461 about?

NCT04426461 is a clinical study titled "Approach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)". Depression and anxiety disorders rank in the top ten causes of years lived with disability. Less than 50% of patients experiencing long-lasting improvements to current gold-standard treatments. Two gold-standard behavioral interventions include behavioral activation, focused on enhancing approach be...

What is the current status of trial NCT04426461?

This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2020-09-11. Estimated completion is 2025-06-30.

What conditions does trial NCT04426461 study?

This clinical trial studies the following conditions: Depression, Anxiety.

What interventions are being tested in trial NCT04426461?

The interventions under investigation include: Behavioral Activation (BEHAVIORAL), Exposure-based therapy (BEHAVIORAL), Supportive therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT04426461?

This trial is sponsored by Laureate Institute for Brain Research, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04426461 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.